PURPOSE: The aim of this study was to investigate the role of platelet-derived growth factor (PDGF) and PDGF receptors (PDGFRs) in the proliferation of human glioblastoma cells as a prerequisite for a new therapeutic approach to the treatment of malignant brain tumors with selective tyrosine kinase inhibitors such as imatinib. METHODS AND RESULTS: In the human glioblastoma cell lines U-87 MG, U-118 MG and U-373 MG different PDGF and PDGFR mRNAs were detected by RT-PCR, and the expression of the receptor proteins was demonstrated by immunostaining and flow cytometry. Moreover, functional activity of PDGFRs was demonstrated in PDGFRbeta expressing glioblastoma cell variants by measuring the mobilization of intracellular Ca(2+) upon PDGF-BB stimulation. However, addition of PDGF-BB to the serum-free culture medium had no stimulatory effect on cell proliferation. Furthermore, cell growth in serum-supplemented and serum-free medium was not affected by imatinib, leflunomide and AG-1296 at therapeutically relevant concentrations. CONCLUSION: Our results suggest that clinical antitumor effects of imatinib on glioblastoma, if any, are not mediated by the PDGFR.
PURPOSE: The aim of this study was to investigate the role of platelet-derived growth factor (PDGF) and PDGF receptors (PDGFRs) in the proliferation of humanglioblastoma cells as a prerequisite for a new therapeutic approach to the treatment of malignant brain tumors with selective tyrosine kinase inhibitors such as imatinib. METHODS AND RESULTS: In the humanglioblastoma cell lines U-87 MG, U-118 MG and U-373 MG different PDGF and PDGFR mRNAs were detected by RT-PCR, and the expression of the receptor proteins was demonstrated by immunostaining and flow cytometry. Moreover, functional activity of PDGFRs was demonstrated in PDGFRbeta expressing glioblastoma cell variants by measuring the mobilization of intracellular Ca(2+) upon PDGF-BB stimulation. However, addition of PDGF-BB to the serum-free culture medium had no stimulatory effect on cell proliferation. Furthermore, cell growth in serum-supplemented and serum-free medium was not affected by imatinib, leflunomide and AG-1296 at therapeutically relevant concentrations. CONCLUSION: Our results suggest that clinical antitumor effects of imatinib on glioblastoma, if any, are not mediated by the PDGFR.
Authors: Frank D Böhmer; Luchezar Karagyozov; Andrea Uecker; Hubert Serve; Alexander Botzki; Siavosh Mahboobi; Stefan Dove Journal: J Biol Chem Date: 2002-11-14 Impact factor: 5.157
Authors: Eric C McGary; Amir Onn; Lisa Mills; Amy Heimberger; Omar Eton; Gary W Thomas; Mikhail Shtivelband; Menashe Bar-Eli Journal: J Invest Dermatol Date: 2004-02 Impact factor: 8.551
Authors: Olga Martinho; Renato Silva-Oliveira; Vera Miranda-Gonçalves; Carlos Clara; José Reynaldo Almeida; André Lopes Carvalho; João Taborda Barata; Rui Manuel Reis Journal: Transl Oncol Date: 2013-04-01 Impact factor: 4.243
Authors: A Vainshtein; L Veenman; A Shterenberg; S Singh; A Masarwa; B Dutta; B Island; E Tsoglin; E Levin; S Leschiner; I Maniv; L Pe'er; I Otradnov; S Zubedat; S Aga-Mizrachi; A Weizman; A Avital; I Marek; M Gavish Journal: Cell Death Discov Date: 2015-11-30
Authors: O Martinho; A Longatto-Filho; M B K Lambros; A Martins; C Pinheiro; A Silva; F Pardal; J Amorim; A Mackay; F Milanezi; N Tamber; K Fenwick; A Ashworth; J S Reis-Filho; J M Lopes; R M Reis Journal: Br J Cancer Date: 2009-08-25 Impact factor: 7.640